Observational studyEuropean journal of neurology2026
Clinical Features and Prognosis of SEPTIN9-Related Hereditary Neuralgic Amyotrophy.
Observational study in European journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SEPTIN9 R106W in a Chinese family with hereditary neuralgic amyotrophy: phenotypic heterogeneity and rehabilitation in a pediatric case.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuralgic amyotrophy (NA) causes acute episodes of neuropathic pain in the upper limbs, followed by weakness and atrophy. NA can be idiopathic (INA) or hereditary (HNA). The SEPTIN9 gene has been linked to HNA. This study aimed to characterize the clinical and prognostic features of patients with SEPTIN9-related HNA.
methodsThis retrospective multicenter study included all adult patients diagnosed with SEPTIN9-related HNA in France from January 2012-June 2025. INA patients were included as controls.
resultsTwelve patients with SEPTIN9-related HNA and 25 with INA were included. A family history of NA (75%) and dysmorphic features (50%) were reported exclusively in the SEPTIN9 group. The median age at neurological episode was significantly lower in the SEPTIN9 group (26.0 years) than in the INA group (38.5 years; p < 0.01). Multiple episodes were more frequent in the SEPTIN9 group (75%) than in the INA group (24%; p < 0.01). Distal upper-limb nerves were more frequently affected in SEPTIN9-related HNA episodes than in INA episodes. Sensory symptoms were significantly more frequent in SEPTIN9-related HNA episodes (57%) than in INA episodes (22%; p < 0.01). A higher proportion of SEPTIN9-related HNA patients had a modified Rankin Scale score ≥ 2 (42%) compared with INA patients (16%), although this difference did not reach statistical significance (p = 0.12).
conclusionsWhile not completely sensitive or specific, certain features may prompt clinicians to suspect a SEPTIN9-related form when assessing a patient with NA: young age, dysmorphic features, a family history of NA, repeated episodes, sensory symptoms, and distal nerve involvement affecting the upper limbs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.